| scholarly article | Q13442814 |
| P2093 | author name string | Sufang Yang | |
| Guohua Liu | |||
| P2860 | cites work | Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy | Q84420289 |
| [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma] | Q95390783 | ||
| Back to the roots: the remarkable RAF oncogene story | Q24322964 | ||
| ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? | Q26744787 | ||
| Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex | Q28285614 | ||
| A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma | Q33426534 | ||
| The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition | Q34202856 | ||
| Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer | Q34342897 | ||
| An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma | Q34611731 | ||
| Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. | Q34632966 | ||
| Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma | Q35023451 | ||
| Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials | Q35166558 | ||
| The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis | Q35441132 | ||
| Biological evaluation of a novel sorafenib analogue, t-CUPM | Q35448698 | ||
| Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions | Q35495325 | ||
| Genome-wide exploration of the molecular evolution and regulatory network of mitogen-activated protein kinase cascades upon multiple stresses in Brachypodium distachyon | Q35505152 | ||
| BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy | Q35723888 | ||
| A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study | Q35748507 | ||
| Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma | Q36093366 | ||
| Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways | Q36139849 | ||
| Targeting oncogenic Ras signaling in hematologic malignancies | Q36352506 | ||
| Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway | Q36557277 | ||
| Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations | Q37269341 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. | Q37457689 | ||
| Leptin induces osteocalcin expression in ATDC5 cells through activation of the MAPK-ERK1/2 signaling pathway | Q37665555 | ||
| The role of signaling pathways in the development and treatment of hepatocellular carcinoma | Q37773788 | ||
| Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development | Q37822317 | ||
| Sorafenib: activity and clinical application in patients with hepatocellular carcinoma | Q37827878 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| MEK inhibitors: a patent review 2008 - 2010. | Q37872791 | ||
| The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. | Q37996420 | ||
| Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting | Q38227885 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives | Q38710627 | ||
| Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation | Q38747966 | ||
| Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells. | Q38756320 | ||
| NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways | Q38940292 | ||
| Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta. | Q39607759 | ||
| AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). | Q39775573 | ||
| Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes | Q39918833 | ||
| Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model | Q40009265 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats | Q40097970 | ||
| Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). | Q40149263 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma | Q40236389 | ||
| The 3Rs of life: Ras, Raf and growth regulation | Q40756295 | ||
| Dislodgment and accelerated degradation of Ras. | Q41061827 | ||
| Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid | Q41294243 | ||
| Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer | Q41503593 | ||
| Somatic changes in primary liver cancer in Russia: a pilot study. | Q42285632 | ||
| Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. | Q42506244 | ||
| Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha | Q42834643 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection | Q45399300 | ||
| Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis | Q45736340 | ||
| Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. | Q45988562 | ||
| The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. | Q46019502 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. | Q47262968 | ||
| Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study. | Q51007060 | ||
| Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. | Q52895369 | ||
| HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. | Q53260500 | ||
| A rare point mutation in the Ras oncogene in hepatocellular carcinoma. | Q53260505 | ||
| Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. | Q54337602 | ||
| Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. | Q54541478 | ||
| Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas | Q63634627 | ||
| u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma | Q74108509 | ||
| Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway | Q74123324 | ||
| Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma | Q74428408 | ||
| Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma | Q80581929 | ||
| Sorafenib exposure decreases over time in patients with hepatocellular carcinoma | Q82263349 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 1041-1047 | |
| P577 | publication date | 2017-01-02 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma | |
| P478 | volume | 13 |
| Q89762212 | Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma |
| Q52716646 | Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro. |
| Q54978010 | Benzo(a)pyrene promotes Hep-G2 cell migration and invasion by upregulating phosphorylated extracellular signal-regulated kinase expression. |
| Q92594846 | Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6 |
| Q49683575 | Capicua suppresses hepatocellular carcinoma progression by controlling ETV4-MMP1 axis |
| Q60312682 | Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence |
| Q89909357 | ERK/MAPK signalling pathway and tumorigenesis |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q91973605 | Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma |
| Q99609568 | Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis |
| Q58693431 | Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma |
| Q89861316 | Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma |
| Q92868057 | NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatoce |
| Q60309369 | Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway |
| Q91633218 | Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway |
| Q92795213 | Peptide V3 Inhibits the Growth of Human Hepatocellular Carcinoma by Inhibiting the Ras/Raf/MEK/ERK Signaling Pathway |
| Q58710795 | Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway |
| Q91644762 | Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy |
| Q54232278 | Role of the ERK1/2 Signaling Pathway in the Replication of Junín and Tacaribe Viruses. |
| Q91755635 | Sphingosine-1-phosphate promotes PDGF-dependent endothelial progenitor cell angiogenesis in human chondrosarcoma cells |
| Q92533640 | TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway |
| Q55437410 | The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. |
| Q90240699 | Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons |
| Q90467727 | Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma |
| Q49646793 | microRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway. |
Search more.